Dr. Jack Rubin MD
Medical Director and Chief Executive Officer , Los Angeles Vascular Center
Member of the Healthcare Council
Council Member Biography
Jack Rubin, MD, has been Medical Director of DaVita Los Angeles Dialysis Center in California since January 1999. Dr. Rubin has also been Medical Director and Chief Executive Officer of Los Angeles Vascular Center (LAVC) in Inglewood, California since June 2006. LAVC performs outpatient procedures to correct problems with vascular accesses in dialysis patients, angiograms of the legs, and stenoses repairs of femoral arteries of the legs in patients with peripheral arterial disease. Dr. Rubin has also testified on behalf of plaintiffs and defendants in malpractice cases in California, Arizona, and Puerto Rico and is Medical Examiner for the California Board of Medicine. Dr. Rubin has been involved in non-healing wound care, and is an expert in the area of decubitus ulcers and their treatment. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Medical Director and Chief Executive Officer , Los Angeles Vascular Center
- 1999 - Unspecified
- Medical Director, Davita Los Angeles Dialysis Center
GLG NewsSM Analyses by Jack Rubin
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Tekturan losers blood pressure and proteinuria simultaneously
May 27, 2008
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com
While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these is proteinuria.
-
November 6, 2006
MEDICARE ADDS PERFORMANCE-BASED PAYMENTS FOR PHYSICIANS | www.cms.hhs.gov
This drug is from a new class of agents that treat type II diabetes. The advantages of this class of drugs is that there is no hypoglycemia nor is there weight gain on those patients being treated with them.
-
Benefits of Novartis Combination Drug Regimen
June 16, 2006
Novartis Reports Two Heart Drugs Are Safe, Effective | online.wsj.com
Novartis is introducing a combination of valosartan and amlodipine to treat hypertension in the marketplace. This is a good combination because those patients who cannot tolerate ACE-I due to cough or, more rarely, angioneurotic edema, can now use this new agent to treat hypertension instead of Lotrel, which has as combination of an ACE-I and amlodipine.
Valosartan offers not only renal and cardiac protection, an effect seen independent of blood pressure control, it also reduces the pedal edema seen in many patients using amlodipine.
Other benefits are having a combination drug giving 2 different acting agents for one copayment price. -
Reduciton of neovascularization using Rosigiltazone
June 16, 2006
Rosiglitazone may delay progression of severe diabetic retinopathy | www.ophthalmologytimes.com
Diabetics had fewer instances of neovascularization of their retinas while using Rosiglitazone.
This could lower the morbidity of diabetic retinopathy in diabetic patients as well as lowering health care cost for diabetic retinopathy in these patients. -
Use of Zerenex in ESRD as a phosphate binder
June 7, 2006
Zerenex in Phase II Clinical Development for Treatment of Hyperphosphatemia in ESRD Patients | www.eneph.com
Zerenex is a phosphate binder that contains iron.
This could be a new phosphate binder without danger of lanthanam build up as could be seen with Fosrenol.
GLG Study Groups with Jack Rubin(?)
| Study Group Name | No. Members |
|---|---|
| Economic Experts on Managed Care | 805 |
| Medicare Experts | 570 |
| Nephrologists (US) | 538 |
| Physicians who Treat Peripheral Vascular Disease | 340 |
| Physicians who Treat End Stage Renal Disease (ESRD) | 150 |
GLG Live Meetings with Jack Rubin(?)
Jack Rubin has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.